Does Adderall (amphetamine and dextroamphetamine) affect liver function tests (LFTs)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Impact of Adderall on Liver Function Tests

Adderall (amphetamine-dextroamphetamine) can potentially cause liver function test abnormalities, though this is a rare adverse effect that is not commonly observed with therapeutic use. While not typically listed as a major concern in most patients, there have been documented cases of liver injury associated with Adderall use.

Evidence for Adderall's Effect on LFTs

Documented Hepatotoxicity

  • There are rare case reports of Adderall-induced acute liver injury in the medical literature 1
  • A case report described a 55-year-old woman who developed acute liver failure while taking prescribed Adderall for ADHD, despite taking it at therapeutic doses 1
  • Patients with underlying liver conditions may be at higher risk for Adderall-related liver injury

Monitoring Recommendations

  • Current guidelines do not specifically mandate routine liver function testing for patients on Adderall, unlike some other psychotropic medications
  • This contrasts with medications like pemoline (another stimulant previously used for ADHD), which was associated with severe hepatotoxicity requiring biweekly liver function testing 2
  • Pemoline was found to cause altered liver function tests in 44 children and total liver failure in 13 children (11 resulting in death or transplantation) 2

Risk Assessment and Monitoring

Baseline Assessment

  • Consider obtaining baseline liver function tests before initiating Adderall therapy, particularly in patients with:
    • Pre-existing liver disease
    • History of alcohol use disorder
    • Concomitant hepatotoxic medications
    • Advanced age

Ongoing Monitoring

  • Routine monitoring of liver function is not specifically mandated for Adderall, unlike other medications such as:
    • Methotrexate, which requires regular monitoring to prevent dose-dependent liver fibrosis 2
    • Acitretin, which can cause elevation in transaminases in 13-16% of patients 2

Signs Requiring Attention

  • Patients on Adderall should be educated about symptoms that might indicate liver dysfunction:
    • Jaundice
    • Right upper quadrant abdominal pain
    • Unexplained fatigue
    • Nausea or vomiting
    • Dark urine or light-colored stools

Management of Abnormal LFTs in Patients on Adderall

If a patient on Adderall develops abnormal liver function tests:

  1. Evaluate the severity of LFT elevation:

    • Mild elevation (less than 3× upper limit of normal): Consider continued monitoring
    • Moderate elevation (3-5× upper limit of normal): Consider temporary discontinuation
    • Severe elevation (>5× upper limit of normal): Discontinue Adderall 2
  2. Rule out other causes of liver dysfunction:

    • Viral hepatitis
    • Alcohol use
    • Other hepatotoxic medications
    • Underlying liver disease
  3. Consider rechallenge only if:

    • LFTs have returned to baseline
    • No alternative explanation for LFT elevation was found
    • Benefits of Adderall therapy clearly outweigh risks

Special Populations

Patients with Pre-existing Liver Disease

  • Use Adderall with caution in patients with known liver disease 1
  • Consider more frequent monitoring of liver function tests
  • Lower starting doses may be appropriate
  • Be vigilant for signs of hepatic decompensation

Alcohol Use Disorder

  • Patients with alcohol-related liver disease may be at higher risk for medication-induced liver injury
  • Liver enzymes are a poor guide to the development of progressive liver fibrosis in alcohol-related liver disease 2
  • Consider non-invasive markers of fibrosis to monitor these patients

Clinical Perspective

While the risk of significant hepatotoxicity with Adderall appears to be low in most patients, clinicians should maintain awareness of this potential adverse effect. The benefit-risk profile remains favorable for most patients with ADHD who require stimulant therapy, but appropriate monitoring and patient education are important components of care.

Unlike medications with well-established hepatotoxic profiles that require mandatory monitoring protocols, Adderall's effects on liver function appear to be idiosyncratic rather than predictable or dose-dependent in most cases.

References

Research

Adderall induced acute liver injury: a rare case and review of the literature.

Case reports in gastrointestinal medicine, 2013

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.